Disease-free survival (DFS / iDFS / EFS)
Oncology· appears in 400+ cited findings in this library
What it is and how the reviews use it
Disease-free survival (DFS / iDFS / EFS) is an endpoint used in clinical trials to measure the length of time after treatment during which a patient stays free of disease. It is a critical measure of treatment efficacy, indicating how long a patient lives without the disease returning or progressing. This endpoint is frequently used in regulatory review documents to assess the benefit of new therapies.
The reviews in this library utilize DFS, iDFS, and EFS in various contexts. For instance, the GENENTECH — Perjeta FDA Review reported a "3 year event-free rate (IDFS)" of 93.2%. The Roche Holding AG — Avastin EMA EPAR variation assessment report noted a "Median Investigator-assessed EFS in Bv + RT/T arm" of 11.3 months. Additionally, the SANOFI AVENTIS US — Taxotere FDA Review presented a "disease-free survival (DFS) hazard ratio" of 0.74.
Real examples — cited to the source page
| MabThera | 3-year EFS for dose-dense rituximab | 95 | Roche Holding AG — MabThera EMA EPAR variation assessment report, p.29 |
| Avastin | Median Investigator-assessed EFS in Bv + RT/T arm | 11.3 | Roche Holding AG — Avastin EMA EPAR variation assessment report, p.9 |
| Qarziba | 1-year EFS rate | 45 | Recordati B V — Qarziba, p.65 |
| Taxotere | disease-free survival (DFS) hazard ratio | 0.74 | SANOFI AVENTIS US — Taxotere FDA Review, p.52 |
| Venclexta | Information Fraction for EFS at IA2 | 87% | AbbVie Inc. — Venclexta FDA Review, p.131 |
| Breyanzi | median Event-free survival (EFS) | 4.99 | Bristol-Myers Squibb Company — Breyanzi EMA EPAR variation assessment, p.16 |
| Lynparza | Hazard ratio for Invasive Disease Free Survival | 0.58 | AstraZeneca PLC — Lynparza FDA Review, p.51 |
Different drugs were studied in different trials — these values are not head-to-head comparisons.
Explore the full evidence
Every Disease-free finding in the library — searchable and answerable in plain language — is in the Oncology research library →
Figures are as stated in the cited source documents. Educational reference only — not medical or investment advice.